Imperva Inc (NYSE:IMPV) Director Anthony J. Bettencourt sold 99,598 shares of the business’s stock in a transaction on Thursday, August 24th. The stock was sold at an average price of $43.59, for a total value of $4,341,476.82. Following the completion of the transaction, the director now directly owns 99,598 shares in the company, valued at approximately $4,341,476.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Imperva Inc (IMPV) opened at 43.25 on Monday. Imperva Inc has a 12-month low of $34.40 and a 12-month high of $57.24. The company has a 50-day moving average price of $46.50 and a 200-day moving average price of $45.52. The company’s market cap is $1.46 billion.

Imperva (NYSE:IMPV) last posted its quarterly earnings results on Thursday, July 27th. The software maker reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by $0.15. Imperva had a negative net margin of 4.69% and a negative return on equity of 5.00%. The business had revenue of $74.44 million for the quarter, compared to analysts’ expectations of $74.30 million. During the same quarter in the previous year, the company earned ($0.23) earnings per share. The business’s quarterly revenue was up 28.6% on a year-over-year basis. On average, analysts predict that Imperva Inc will post $0.81 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Imperva Inc (IMPV) Director Sells 99,598 Shares of Stock” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/28/insider-selling-imperva-inc-impv-director-sells-99598-shares-of-stock.html.

A number of equities research analysts have recently weighed in on the company. Stifel Nicolaus restated a “hold” rating and set a $47.00 target price on shares of Imperva in a research report on Friday, July 14th. UBS AG assumed coverage on Imperva in a research report on Tuesday, June 6th. They set a “positive” rating and a $60.00 target price for the company. ValuEngine downgraded Imperva from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Piper Jaffray Companies restated a “buy” rating and set a $58.00 target price on shares of Imperva in a research report on Monday. Finally, Imperial Capital restated an “outperform” rating and set a $57.00 target price (up previously from $55.00) on shares of Imperva in a research report on Tuesday, May 9th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $51.61.

Hedge funds have recently bought and sold shares of the company. ETF Managers Group LLC purchased a new stake in Imperva during the second quarter worth $41,888,000. North Run Capital LP raised its stake in Imperva by 999.3% in the first quarter. North Run Capital LP now owns 750,000 shares of the software maker’s stock worth $30,788,000 after buying an additional 681,772 shares in the last quarter. Clearbridge Investments LLC raised its stake in Imperva by 47.0% in the first quarter. Clearbridge Investments LLC now owns 1,262,507 shares of the software maker’s stock worth $51,826,000 after buying an additional 403,809 shares in the last quarter. BlackRock Inc. raised its stake in Imperva by 11.3% in the second quarter. BlackRock Inc. now owns 2,124,043 shares of the software maker’s stock worth $101,635,000 after buying an additional 215,170 shares in the last quarter. Finally, BNP Paribas Arbitrage SA raised its stake in Imperva by 8,392.3% in the first quarter. BNP Paribas Arbitrage SA now owns 200,927 shares of the software maker’s stock worth $8,248,000 after buying an additional 198,561 shares in the last quarter. Institutional investors own 92.72% of the company’s stock.

About Imperva

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.

Insider Buying and Selling by Quarter for Imperva (NYSE:IMPV)

Receive News & Stock Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related stocks with our FREE daily email newsletter.